A Phase II, Randomized, Double-Blind, Cross-Over Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-Glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease
Latest Information Update: 31 Oct 2025
At a glance
- Drugs Ensifentrine/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Verona Pharma
Most Recent Events
- 28 Oct 2025 Planned End Date changed from 23 Feb 2026 to 9 Dec 2025.
- 28 Oct 2025 Planned primary completion date changed from 23 Feb 2026 to 9 Dec 2025.
- 28 Oct 2025 Status changed from recruiting to active, no longer recruiting.